Genomics (TXG) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

EST Cathie Wood’s ARK Investment buys 120K shares of 10x Genomics (TXG) todayMaximize Your Portfolio with Data Driven Insights:Leverage ...

10x Genomics, Inc. (NASDAQ:TXG)'s strong portfolio of intellectual property and the widespread recognition of its products show its commitment to innovation. The company has recently placed a high ...

10X Genomics, Inc. is a life science technology company, which engages in building products to interrogate, understand and master biology. Its integrated solutions include single cell ...

CEO Serge Saxonov, PhD, says provider of single cell, spatial, and in situ instruments expects to see benefits from sales ...

Furthermore, the services segment experienced robust year-over-year and quarter-over-quarter growth, showcasing 10x Genomics’s ability to expand its offerings and enhance its market position.

10x Genomics excels in single-cell and spatial technologies but faces significant challenges. Despite an EPS beat, revenue fell 1% due to sales disruption and competitive pricing. The company's ...

PLEASANTON, Calif., Jan. 2, 2025 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, announced today that members of its management team will present at ...

10x Genomics delivers powerful, reliable tools that fuel scientific discoveries and drive exponential progress to master biology and to advance human health. Cited in more than 7,000 research papers, ...